NYSE:NVST

20.02
0.13 (0.65%) 1d
0
Investor Insights

This summary was created by AI, based on 2 opinions in the last 12 months.

The experts' reviews on NVST-N from Envista Holdings point to challenges in the dental industry due to a slowdown in the economy and household income, as well as delays in expansion plans for dental offices. The company also faced setbacks in Russia and China, along with disruptions in manufacturing in Israel. Additionally, the decision to sell non-core businesses and the weakened performance of the adult liner business have affected the company's growth and margin targets.

Consensus
Sell
Valuation
Fair Value
SELL
Envista Holdings

She sold. Late to the game in launching a clear liner in lieu of braces. Slowdown in economy and household income means dental visits get cut. She misjudged how cyclical dental industry can be, not everyone gets coverage. Russian business hurt, China slowed, Israel manufacturing disrupted. Don't buy the dip.

Healthcare
SELL
Envista Holdings

Sold non-core businesses. With interest rates rising, dental offices delayed expansion plans. Operating in Russia, slowdown there. Liner business for adults weakened. May need to review core grow and margin targets. See her Top Picks.

Healthcare
SELL
Envista Holdings

Numerous headwinds. Russian war, economic softening, price competition, higher interest rates, war in Israel disrupting supply. Not clear when these clouds will dissipate. She sold, took the loss, bought more TMO.

Healthcare
DON'T BUY
Envista Holdings
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

NVST is a $4.5B market cap company serving the dental industry. It is reasonably-priced at 14X earnings. Net debt of $800M is fairly high compared with $235M cash flow in the last year. Cash flow is decent, and steady, but we do note that sales are essentially the same level as nearly eight years ago. It has been consistently profitable, but EPS next year is expected to be slightly lower than it was in 2016. Even with no growth, the company pays no dividend. Insiders own less than 0.5%. On the positive side, sharecount has not changed in many years. It typically beats estimates, but there is very little excitement here. We would be more interested in it as a value stock if debt was lower. As it stands, we would pass. 
Unlock Premium - Try 5i Free

Healthcare
HOLD
Envista Holdings

Increased investments in R&D. Divested low-growth areas, repositioning for the future. Dental visits were down during Covid. Headwinds in Russia and China have hurt. She's underwater, but management is doing the right things. In US, dental costs are more discretionary. Demographics and low EM penetration rates are tailwinds.

Healthcare
PAST TOP PICK
Envista Holdings
(A Top Pick Oct 13/21, Down 11%) Likes it because the dental penetration rate in emerging markets remains low, though it's a mature market in North America. Only a third of the population in the latter holds no dental coverage, so fears of a recession have pressured shares. Also, their exposure to Russia and China haven't hurt, though it has been recovering in China. Aging demographics is seeing maintaining teeth rather than dentures.
Healthcare
PAST TOP PICK
Envista Holdings

(A Top Pick Sep 14/21, Down 23%) A leading provider of dental products and services. A spin-off from Danaher. A reason NVST is down is that dental expenses are only partially (50%) covered by plans, so people may defer going to the dentist. Also, 15% of their revenues are from Russia and China (impacted by lockdowns). That's a hiccup. Is trading cheaply now, and she likes the long-term prospects. NVST is introducing new popular products like new implants.

Healthcare
BUY
Envista Holdings

She started buying this last year. They revamped their dental product lines, which are doing well. Dental care has room to grown in emerging, markets, though mature in North America. She sees 10% upside one year out. Likes it.

Healthcare
BUY
Envista Holdings
A past top pick. She likes their long-term growth outlook because of demographics and penetrating emerging markets where dentistry penetration remains low. Danaher spun out Envista to focus more on healthcare R&D, which has worked out. She sees mid-single-digit top-line growth and margin improvement in NVST.
Healthcare
BUY
Envista Holdings
It got spun out in late 2019. The dental sector has a lot of room to grow as the population ages and needs more dental care in North America. In developing markets there's a lot of room to grow; they need more dental hygiene. ENST has been investing in R&D, previously lagging, and are now leaders in implants. Lots going on. They sell products directly and indirectly, so they have channels to sell new innovative products. Trades at a reasonable PE.
Healthcare
BUY ON WEAKNESS
Envista Holdings
Reported a good quarter. Her target price is closer to $50, so she's not buying it right now. On a weak day, you could start or add to your position.
Healthcare
TOP PICK
Envista Holdings
Dental products, with a broad range. Spun off from Danaher, allowing them to focus on improvements. Quite global, with only 48% of revenues coming from North America. Leading player in implants, a growing segment. Good growth in both developed and developing markets. Likes the valuation and its industry position. No dividend. (Analysts’ price target is $50.57)
Healthcare
BUY
Envista Holdings
They make dental products. She likes the dental industry for its secular growth, specifically from aging demographics (a desire to keep your teeth longer which feeds the implant business), and a low penetration rate in developing markets. 22% of their revenues come from emerging markets, plus 50% from North America. There's a lot of room for NVST to grow and they have a broad product offering, supplying 90% of the equipment of what a dentist needs. They lead in many product categories. They just launched the Sparks clear dental liner which is enjoying strong growth int he U.S., the first innovation in years. They're #1 in the implant business. (Analysts’ price target is $51.75)
Healthcare
Showing 1 to 13 of 13 entries
  • «
  • 1
  • »

Envista Holdings(NVST-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 2

Stockchase rating for Envista Holdings is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Envista Holdings(NVST-N) Frequently Asked Questions

What is Envista Holdings stock symbol?

Envista Holdings is a American stock, trading under the symbol NVST-N on the New York Stock Exchange (NVST). It is usually referred to as NYSE:NVST or NVST-N

Is Envista Holdings a buy or a sell?

In the last year, 2 stock analysts published opinions about NVST-N. 0 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Envista Holdings.

Is Envista Holdings a good investment or a top pick?

Envista Holdings was recommended as a Top Pick by on . Read the latest stock experts ratings for Envista Holdings.

Why is Envista Holdings stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Envista Holdings worth watching?

2 stock analysts on Stockchase covered Envista Holdings In the last year. It is a trending stock that is worth watching.

What is Envista Holdings stock price?

On 2024-12-09, Envista Holdings (NVST-N) stock closed at a price of $20.02.